FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000040775> ?p ?o ?g. }

• W3000040775 endingPage "114" @default.
• W3000040775 startingPage "106" @default.
• W3000040775 abstract "Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial.REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c was 9·5% or less (with no lower limit) on stable doses of up to two oral glucose-lowering drugs with or without basal insulin therapy were eligible if their body-mass index was at least 23 kg/m2. Participants were randomly assigned (1:1) to weekly subcutaneous injections of either masked dulaglutide 1·5 mg or the same volume of masked placebo (containing the same excipients but without dulaglutide). Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked. During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week. Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined. Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until 1200 confirmed primary outcomes accrued. The primary endpoint was the first occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes. All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials.gov, number NCT01394952.Between Aug 18, 2011, and Aug 14, 2013, we screened 12 133 patients, of whom 9901 with type 2 diabetes and additional cardiovascular risk factors were randomly assigned to either dulaglutide (n=4949) or an equal volume of placebo (n=4952). During a median follow-up of 5·4 years, cerebrovascular and other cardiovascular outcomes were ascertained and adjudicated. 158 (3·2%) of 4949 participants assigned to dulaglutide and 205 (4·1%) of 4952 participants assigned to placebo had a stroke during follow-up (hazard ratio [HR] 0·76, 95% CI 0·62-0·94; p=0·010). Dulaglutide reduced ischaemic stroke (0·75, 0·59-0·94, p=0·012) but had no effect on haemorrhagic stroke (1·05, 0·55-1·99; p=0·89). Dulaglutide also reduced the composite of non-fatal stroke or all-cause death (0·88, 0·79-0·98; p=0·017) and disabling stroke (0·74, 0·56-0·99; p=0·042). The degree of disability after stroke did not differ by treatment group.Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity.Eli Lilly and Company." @default.
• W3000040775 created "2020-01-23" @default.
• W3000040775 creator A5000849073 @default.
• W3000040775 creator A5005414020 @default.
• W3000040775 creator A5005906845 @default.
• W3000040775 creator A5006628692 @default.
• W3000040775 creator A5013408607 @default.
• W3000040775 creator A5024475260 @default.
• W3000040775 creator A5026568725 @default.
• W3000040775 creator A5027812322 @default.
• W3000040775 creator A5038086852 @default.
• W3000040775 creator A5041291525 @default.
• W3000040775 creator A5041670111 @default.
• W3000040775 creator A5041974328 @default.
• W3000040775 creator A5042971997 @default.
• W3000040775 creator A5043108571 @default.
• W3000040775 creator A5051731762 @default.
• W3000040775 creator A5052329017 @default.
• W3000040775 creator A5052672899 @default.
• W3000040775 creator A5055443598 @default.
• W3000040775 creator A5056252103 @default.
• W3000040775 creator A5057242778 @default.
• W3000040775 creator A5060545924 @default.
• W3000040775 creator A5072590707 @default.
• W3000040775 creator A5078130962 @default.
• W3000040775 creator A5080292021 @default.
• W3000040775 creator A5080414941 @default.
• W3000040775 creator A5084120269 @default.
• W3000040775 creator A5086287744 @default.
• W3000040775 creator A5086589108 @default.
• W3000040775 creator A5086609118 @default.
• W3000040775 date "2020-02-01" @default.
• W3000040775 modified "2023-10-18" @default.
• W3000040775 title "The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial" @default.
• W3000040775 cites W2274836352 @default.
• W3000040775 cites W2399659685 @default.
• W3000040775 cites W2414005931 @default.
• W3000040775 cites W2604277961 @default.
• W3000040775 cites W2621101635 @default.
• W3000040775 cites W2621487800 @default.
• W3000040775 cites W2748692931 @default.
• W3000040775 cites W2772204795 @default.
• W3000040775 cites W2790574529 @default.
• W3000040775 cites W2791751350 @default.
• W3000040775 cites W2890783608 @default.
• W3000040775 cites W2892247024 @default.
• W3000040775 cites W2908457468 @default.
• W3000040775 cites W2908687677 @default.
• W3000040775 cites W2912733453 @default.
• W3000040775 cites W2914868910 @default.
• W3000040775 cites W2948519518 @default.
• W3000040775 cites W2948602156 @default.
• W3000040775 cites W2948612418 @default.
• W3000040775 cites W2950861759 @default.
• W3000040775 cites W2966070710 @default.
• W3000040775 cites W2968073288 @default.
• W3000040775 cites W2980881483 @default.
• W3000040775 doi "https://doi.org/10.1016/s2213-8587(19)30423-1" @default.
• W3000040775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31924562" @default.
• W3000040775 hasPublicationYear "2020" @default.
• W3000040775 type Work @default.
• W3000040775 sameAs 3000040775 @default.
• W3000040775 citedByCount "68" @default.
• W3000040775 countsByYear W30000407752020 @default.
• W3000040775 countsByYear W30000407752021 @default.
• W3000040775 countsByYear W30000407752022 @default.
• W3000040775 countsByYear W30000407752023 @default.
• W3000040775 crossrefType "journal-article" @default.
• W3000040775 hasAuthorship W3000040775A5000849073 @default.
• W3000040775 hasAuthorship W3000040775A5005414020 @default.
• W3000040775 hasAuthorship W3000040775A5005906845 @default.
• W3000040775 hasAuthorship W3000040775A5006628692 @default.
• W3000040775 hasAuthorship W3000040775A5013408607 @default.
• W3000040775 hasAuthorship W3000040775A5024475260 @default.
• W3000040775 hasAuthorship W3000040775A5026568725 @default.
• W3000040775 hasAuthorship W3000040775A5027812322 @default.
• W3000040775 hasAuthorship W3000040775A5038086852 @default.
• W3000040775 hasAuthorship W3000040775A5041291525 @default.
• W3000040775 hasAuthorship W3000040775A5041670111 @default.
• W3000040775 hasAuthorship W3000040775A5041974328 @default.
• W3000040775 hasAuthorship W3000040775A5042971997 @default.
• W3000040775 hasAuthorship W3000040775A5043108571 @default.
• W3000040775 hasAuthorship W3000040775A5051731762 @default.
• W3000040775 hasAuthorship W3000040775A5052329017 @default.
• W3000040775 hasAuthorship W3000040775A5052672899 @default.
• W3000040775 hasAuthorship W3000040775A5055443598 @default.
• W3000040775 hasAuthorship W3000040775A5056252103 @default.
• W3000040775 hasAuthorship W3000040775A5057242778 @default.
• W3000040775 hasAuthorship W3000040775A5060545924 @default.
• W3000040775 hasAuthorship W3000040775A5072590707 @default.
• W3000040775 hasAuthorship W3000040775A5078130962 @default.
• W3000040775 hasAuthorship W3000040775A5080292021 @default.
• W3000040775 hasAuthorship W3000040775A5080414941 @default.
• W3000040775 hasAuthorship W3000040775A5084120269 @default.
• W3000040775 hasAuthorship W3000040775A5086287744 @default.
• W3000040775 hasAuthorship W3000040775A5086589108 @default.
• W3000040775 hasAuthorship W3000040775A5086609118 @default.
• W3000040775 hasConcept C126322002 @default.

• next